Polyrizon Ltd. has announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform.
The study, conducted in collaboration with the University of Parma in Italy, demonstrated targeted deposition in the nasal vestibule—the key anatomical site for early allergen contact—reinforcing the product’s potential as a barrier-forming treatment for allergic rhinitis.
The evaluation was led by Fabio Sonvico from the Department of Food and Drug at the University of Parma, a leading authority in intranasal and pulmonary drug delivery and a member of Polyrizon’s Scientific Advisory Board. Using a validated silicone-based human nasal cast and fluorescein-labelled imaging, the study assessed the spray deposition profile of PL-14 when administered under clinically relevant conditions.
The results revealed that the PL-14 formulation achieved over 60% deposition in the nasal vestibule, the first physiological region exposed to airborne allergens. This targeted delivery is critical for effectively blocking allergen contact with the nasal mucosa, supporting the mechanism of action of PL-14 as a physical barrier product designed to capture and contain environmental allergens before they trigger an immune response.
“We believe that the ability of our C&C platform to deliver a high concentration of hydrogel barrier to the vestibular region of the nose is a significant step forward,” said Tomer Izraeli, CEO of Polyrizon.
“These results support the core principle behind our blocker products—to form a protective layer at the point of allergen entry and prevent the initiation of allergic reactions.”
PL-14’s performance in this nasal cast model highlights its potential to become a frontline preventive treatment for allergic rhinitis. The hydrogel formulation also maintained favourable sprayability and coverage under standard administration angles, demonstrating its practicality for self-administration.
Polyrizon plans to continue preclinical validation and advance toward clinical trials as part of the development path for the C&C platform.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
